MYCN and neuroblastoma: Consistently, circa 20–30% of all NB cases bear MYCN amplification, equating to 40–50% of all high-risk cases, while the amplification of MYCN is the greatest predictor of poor prognosis, since the status of this oncogene correlated with disease aggression and resistance to treatment [5,6].